Checkpoint Inhibitors Plus Antiangiogenics in Liver Cancer
In the evolving landscape of cancer therapeutics, a recent retrospective study from Beijing You’an Hospital provides an insightful comparison of immune checkpoint inhibitors (ICIs) combined...
















